Trials / Completed

CompletedNCT00440492

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis

An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: —

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex: All
Age: 18 Years – 75 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if PLA-695 changes the blood concentrations of methotrexate when administered together.

Conditions

Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	PLA-695

Timeline

Start date: 2006-12-01
Completion: 2007-11-01
First posted: 2007-02-27
Last updated: 2007-12-13

Locations

9 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT00440492. Inclusion in this directory is not an endorsement.